EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study

Patrick Vermersch iD, Sophie Arnould, Ralf Gold, Ludwig Kappos, Robert Fox, Amit Bar-Or, Bruce A C Cree, Soudeh Ansari, Daniela Piani Meier, Goeril Karlsson, Nicolas Rouyrre iD, Gavin Giovannoni iD

European Journal of Neurology · 2026-06 · 33 (6)

DOI: 10.1111/ene.70659 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Neurology, online erschienen am 08.06.2026. Verfasst von Patrick Vermersch und 11 weiteren Autor:innen. Beteiligte Einrichtung: Université de Lille, Inserm U1172 LilNCog, FHU Precise, Lille, France. Hauptthemen laut MEDLINE: Multiple Sclerosis, Chronic Progressive, Benzyl Compounds, Azetidines, Wheelchairs. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis pharma AG basel switzerland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Delaying time to requiring a wheelchair in people living with MS is an important treatment goal to maintain quality of life and guard against increased healthcare costs. In this post hoc analysis, the effects of siponimod versus placebo on time to sustained Expanded Disability Status Scale (EDSS) ≥ 7.0 over the core part of the Phase 3 EXPAND study were assessed.

Methods

The time to sustained EDSS ≥ 7.0 (time to requiring a wheelchair) was analysed for participants with secondary progressive multiple sclerosis (SPMS). Analyses were based on a While on Treatment (WOT) set that censored participants if entering open‐label treatment. Subgroup analyses were conducted in participants with active versus non‐active SPMS (defined based on pre‐study/baseline criteria), and in participants with baseline EDSS 6.5.

Results

In the overall EXPAND population, siponimod reduced the risk of reaching sustained EDSS ≥ 7.0 (requiring a wheelchair) by 40% (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.41–0.88; p = 0.009) versus placebo; the reduction in risk was 51% (HR, 0.49; 95% CI, 0.29–0.81; p = 0.005) versus placebo in participants with active SPMS and 22% (HR, 0.78; 95% CI, 0.42–1.45; p = 0.437) in non‐active SPMS.

Conclusion

Siponimod reduced the risk of requiring a wheelchair in participants with SPMS versus participants receiving placebo, with a greater effect in those with active disease. Time to requiring a wheelchair is a highly relevant treatment goal and an important indicator of treatment effect in patients with SPMS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple Sclerosis, Chronic ProgressiveBenzyl CompoundsAzetidinesWheelchairsSphingosine 1 Phosphate Receptor ModulatorsHumansDisease ProgressionFemaleMiddle AgedMaleDouble-Blind MethodAdult

Stichwörter der Autor:innen

Markov modelmulti‐state modelsecondary progressive multiple sclerosissiponimodsustained EDSS ≥ 7.0wheelchair

Substanzen

siponimodBenzyl CompoundsAzetidinesSphingosine 1 Phosphate Receptor Modulators

Autor:innen und Institutionen

  • Université de Lille, Inserm U1172 LilNCog, FHU Precise, Lille, France.
  • Sanofi, Zwijnaarde (Gent), Belgium.
  • Department of Neurology, St Josef's Hospital, Ruhr University Bochum, Bochum, Germany.
  • Department of Head, Organs, Movement and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and Uni…
  • Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Neurology, Perelman School of Medicine, Center for Neuroinflammation and Experimental Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Patrick Vermersch, Nicolas Rouyrre, Gavin Giovannoni

Förderung

  • Novartis pharma AG basel switzerland

Zitieren

APA

Vermersch, P., Arnould, S., Gold, R., Kappos, L., Fox, R., Bar-Or, A., Cree, B. A. C., Ansari, S., Meier, D. P., Karlsson, G., Rouyrre, N., & Giovannoni, G. (2026). Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study. European Journal of Neurology, 33(6). https://doi.org/10.1111/ene.70659

Vancouver

Vermersch P, Arnould S, Gold R, Kappos L, Fox R, Bar-Or A, et al. Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study. European Journal of Neurology. 2026;33(6). doi:10.1111/ene.70659

BibTeX
@article{Vermersch2026,
  author = {Vermersch, Patrick and Arnould, Sophie and Gold, Ralf and Kappos, Ludwig and Fox, Robert and Bar-Or, Amit and Cree, Bruce A C and Ansari, Soudeh and Meier, Daniela Piani and Karlsson, Goeril and Rouyrre, Nicolas and Giovannoni, Gavin},
  title = {Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {6},
  doi = {10.1111/ene.70659}
}
Kostenlos starten →